Collaborating for Change - New research alliance to accelerate therapies

Spinal Research and the Christopher & Dana Reeve Foundation (Reeve Foundation) today announced a joint approach to their research strategies with a focus on accelerating the progress of therapies and their delivery to the millions of people around the world living with the life-altering effects of paralysis.

Sharing Knowledge, Resources and Experience

For 40 years, both organisations have shared a commitment to bringing therapeutics that restore function and independence to the spinal cord injury (SCI) community. This new alliance, inspired by the speed at which solutions for COVID-19 are being delivered, seeks to take a coordinated, global approach to accelerating the processes of bringing meaningful therapeutics to those living with SCI.

The new Chief Executive of Spinal Research, Harvey Sihota commented, "We have seen major advances in our understanding of spinal cord biology, including improvements in diagnostics, acute treatment and rehabilitation.

Building on these medical advances, we are now seeking to accelerate processes which can bring restorative treatments to those living with SCI. Given the complexity and scale of the challenge, we see a unified approach as critical to success."

A Blueprint for Speed

At the core of this alliance is a collaborative blueprint to accelerate the development and delivery of meaningful therapeutics. This will establish a framework for decision-making, planning and governance to advance the most promising therapies from the preclinical stage through clinical trials and into medical practice.

The alliance is focusing on combinatorial interventions, innovative protocols and broader stakeholder engagement for fast-tracking these interventions through the translation stage.

Jay Shepard, Chairman of the Reeve Foundation Board of Directors remarked, “This collaborative strategy will address critical systemic issues -- including preclinical testing, optimised clinical trial design, regulatory considerations, intellectual property and the feasibility of commercialisation – that are key to bringing novel therapies to market and ensuring access for the paralysis community.”